- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.08. | Ultragenyx, after setbacks, nabs first gene therapy approval | ||
| 19.08. | Trump reportedly plans to tap policy aide Overton to lead FDA | ||
| 19.08. | Moderna and Merck cancer vaccine returns 'landmark' result in melanoma | ||
| 18.08. | BioMarin acquires experimental drug for rare bone disorder in $275M deal | ||
| 18.08. | Leo Pharma buys rare skin disease drug in $435M deal | ||
| 18.08. | AstraZeneca's win in lung cancer; Sandoz inks a China deal | ||
| 18.08. | Amylyx's bet on a GLP-1 blocker pays off | ||
| 17.08. | Argenx jumps on Phase 3 data for blockbuster Vyvgart | ||
| 17.08. | AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer | ||
| 17.08. | Slate Medicines, Fulcrum Therapeutics to combine in reverse merger | ||
| 17.08. | EyePoint plummets on pivotal data for main drug | ||
| 14.08. | Bristol Myers wins 'milestone' FDA approval of myeloma drug acquired from Celgene | ||
| 14.08. | Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers | ||
| 14.08. | Biotech initiatives pick up as more regions race to become hubs | ||
| 13.08. | New Taiho, Cullinan data heats up lung cancer drug battle | ||
| 13.08. | PTC takes a chance on Sangamo's Fabry disease gene therapy | ||
| 12.08. | Lilly files six lawsuits in bid to shut down 'black market' for retatrutide | ||
| 12.08. | Psychedelics developer Definium scores more positive data for LSD pill | ||
| 12.08. | Silence cashes in on 'differentiated' data; UK reaffirms support for childhood vaccines | ||
| 12.08. | Boulevard starts up with $65M to pursue targeted autoimmune drugs | ||
| 11.08. | Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs | ||
| 11.08. | Chasing Dupixent, a biotech aims to make better antibody drugs for eczema | ||
| 11.08. | Trump signs order seeking to upend childhood vaccine schedule | ||
| 11.08. | Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease | ||
| 11.08. | Vaderis hauls in $152M to test an AKT-targeting drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.